Vidac Pharma's stock currently offers very exciting catch-up potential. The share price development is clearly lagging behind the positive news flow. Analysts even believe that the share price could multiply. The key price drivers are the two oncological and onco-dermatological drug candidates, VDA-1275 and VDA-1102. They are based on Vidac's patented approach of reversing the malignant metabolism of cancer cells and restoring normal cell function. This would represent a new class in cancer treatment.
News & Events